Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 02:02 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a material positive catalyst that drove a 177% stock surge. The evidence supports a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 01:57 AM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, showing longer progression-free survival compared to Keytruda alone. This is a material positive catalyst for Moderna, and the stock surged 177% on the news.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 01:52 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, the first large late-stage study of a custom cancer therapy using mRNA technology. Patients receiving the custom shot plus Keytruda went longer without cancer returning or spreading. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 01:47 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 01:42 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, causing a 177% stock surge. This is a material positive catalyst indicating improved expected fundamentals.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 01:37 AM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom treatment plus Keytruda going longer without cancer recurrence, and shares surged 177%, a material positive catalyst.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 01:32 AM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, showing longer recurrence-free survival compared to Keytruda alone. This is a material positive catalyst for Moderna, supporting a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 01:27 AM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence, and shares surged 177%. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 01:22 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine in combination with Keytruda, showing improved recurrence-free survival in melanoma patients. The stock surged 177% on the news, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 28, 2026, 01:17 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, leading to a 177% stock surge. This is a material positive catalyst for the company.